BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 2, 2004
View Archived Issues
Effective cytolysis of Hodgkin's lymphoma tumor cells by antibody-cytokine fusion protein
Read More
Phase II study of GDNF for Parkinson's fails to meet primary endpoint
Read More
Priority review and accelerated approval designations for Antegren BLA
Read More
Aplidin receives orphan drug status for ALL
Read More
NX-1207 shows potential as a front-line treatment for BPH in phase I/II trials
Read More
FDA accepts IND for MN-029
Read More
Fast track status for INO-1001 for patients with STEMI
Read More
IND accepted for phase II trials of ORG-25969
Read More
Favorable results for ACP-103 for use in Parkinson's patients
Read More
Exelixis submits IND for XL-999
Read More
Europe's CHMP hands down positive opinion for MabThera in indolent NHL
Read More
Bionomics progress in gene test for epilepsy
Read More
Retinoic metabolism inhibitors promising against prostate cancer
Read More
Novel SERM with minimal ovarian effects
Read More
New melatonin receptor ligands prepared and tested by French scientists
Read More
Novel modulators of nAChR and monoamine receptors or transporters claimed by NeuroSearch
Read More
Servier researchers describe novel cognition-enhancing agents
Read More
New IGF-1R inhibitors with potential in cancer therapy
Read More
Novel topoisomerase inhibitors identified by researchers at State U. of New Jersey
Read More
Novel fusion-targeting antiviral agents presented by Trimeris
Read More
New MCH receptor modulators in early development at Tularik
Read More
Femara sNDA granted priority review by FDA
Read More
Erbitux receives E.U. approval for metastatic colorectal cancer
Read More
FDA clears IND for study of VPI-013 in patients with major depressive disorder
Read More
IND submission to start phase I trial of thrombin inhibitor ARC-183
Read More
Enrollment open in phase III trial of Veronate
Read More
Tularik stockholders to meet in August to vote on acquisition by Amgen
Read More
Arava approved in Europe for active psoriatic arthritis
Read More
Vasopressin V2 receptor antagonist effective aquaretic in vivo
Read More
PXD-101 enters phase I trial in hematologic cancer
Read More
Exenatide NDA submission for type 2 diabetes
Read More
Selective glucocorticoid receptor modulator may prevent progression of multiple sclerosis
Read More